Innovation Pharmaceuticals Inc (IPIX)

[petemantx]

Your article looks good for B and the anti-bacterial side of things and the big study of 20 viruses done over 2022 and possibly even late 2021 is due to be released sometime in Sept or Oct if I remember correctly. That should give Brilacidin a good deal of exposure on the anti-viral front but to be honest prior studies have not done that much for B and IPIX. How much did the white paper on Brilacidin that was sent to all the world's immunologists spur in the way of expedited investigation. To date looks pretty paltry.

I still am leaning towards S. America and the anti-fungal properties of Brilacidin taking the lead in bringing B to marketability. S. American as anxious as IPIX to get B to market to start generating revenues for them (they signed a deal w/ IPIX already regarding anything they bring to market using B) and they also need it to raise their legitimacy in the world of medical research per their own admission.

Your antibacterial study mentioned "Importantly, compound 30 showed potent in vivo efficacy in a murine model of bacterial keratitis
The S. America article said that B showed promise for anti-fungal keratitis which blinds over 1MM people / year.

I looked up keratitis and it is simply the inflammation (B is also a very strong anti-inflammatory) of the cornea. Some are bacterial related, some fungal, and can either be infectious or non-infectious (as due to an injury). What I found on line is that most are easily treatable but obviously some of the infectious types (bacterial, fungal) are quite severe. Hope Brilaicidin can be found as a treatment for these conditions.